Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10
Lake Street analyst Thomas Flaten initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $10.
Stocks · News reference
Alterity Therapeutics Says ATH434 50 mg Slowed Multiple System Atrophy Decline By About 52% In Post Hoc Phase 2 Analysis
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
The multiple system atrophy (MSA) clinical trial pipeline is experiencing significant momentum with 22+ companies developing 24+ pipeline drugs. The pipeline is diversifying beyond traditional approaches to include oral small molecules, cell replacement therapies, gene therapies, and next-generation alpha-synuclein inhibitors. Recent developments include Alterity Therapeutics achieving FDA alignment on Phase III for ATH434, Teva receiving Fast Track designation for TEV-56286, and iRegene Therapeutics enrolling the first patient in a randomized controlled trial for NouvNeu004 in China.
Alterity Therapeutics shares are trading higher after the company announced it was granted a new composition of mater patent for ATH434 by the U.S. Patent and Trademark Office.